With progress plateauing for a second consecutive year and global financing also levelling off, the WHO has called for a ‘high burden to high impact’ country-led strategy.
Browsing: Parasitic > Protozoan Infections
Researchers from Imperial College London have reported their recent success in using ‘gene drive’ technology to block female mosquito reproduction, resulting in the total collapse of caged populations of Anopheles gambiae in as little as 7–11 generations.
Genomics is increasingly being adopted into both research and clinical settings. Here, we speak to Dyann Wirth about the use of genomics in the field of malaria, from what it can uncover about the parasite to the hurdles that need to be overcome moving towards elimination.
Cerebral malaria is the most severe neurological complication of Plasmodium falciparum infection. Here, the authors discuss how NRG-1 could attenuate brain injury and mortality.
The US FDA have approved Krintafel (tafenoquine) for the radical cure of Plasmodium vivax malaria infections, the first approval for such a drug in 50 years.
In this infographic we take a look at the estimated burden of some key foodborne diseases in terms of both cases and mortality.
Recent technological advancements have allowed organoids to become a viable research tool for a wide range of development and disease models. Here, we look at some of the research that’s been done in infectious diseases and delve into what the future of organoids might look like.
A new study has estimated that up to 30% of parasite burden could be in the liver and bone marrow of infected individuals, a reservoir that has previously gone undetected and unstudied.
The largest genetic study of malaria parasites in Southeast Asia has revealed that resistance to the most powerful antimalarial drugs has been spreading unreported for years in Cambodia.
In this article, from Future Medicinal Chemistry, the researchers synthesize a new series of pyrazolo[1,5-c]pyrimidines via hybridization strategies and evaluate these for in vitro activity against leishmaniasis